Manufacturer of precision-guided therapy tools Volcano has initiated the limited market release of its US Food and Drug Administration (FDA) cleared and CE Marked SyncVision technology system in the US and Europe.

An online image processing workstation, SyncVision technology system is designed for coronary catheterisations.

Using this technology, the physician can navigate simultaneously on an angiogram and correlate significant IVUS findings with the corresponding spots using co-registration of the Eagle Eye Platinum catheter with x-ray angiography.

SyncVision provides the detailed vessel, lumen and wall structure from angiography and the spatial localisation of Volcano’s intravascular ultrasound images within the coronary tree together in a co-registered view to facilitate more informed treatment decisions and more efficient, enhanced workflow performance.

"It also allows for simple and precise length measurements to help inform stent selection."

University of Washington Medical Center director of cardiac catheterisation laboratory Dr Steven Goldberg said SyncVision allows correlation of significant IVUS findings with the corresponding spots on the angiogram.

"This addresses a challenging aspect of current practice in that it can be difficult to identify the precise spot needing treatment in translating the IVUS findings to the angiogram," Dr Goldberg said.

"It also allows for simple and precise length measurements to help inform stent selection. Co-registration of different imaging modalities is currently the wave in interventional cardiology, and I think this is one of the most useful and user friendly co-registration formats I have seen. I believe that this truly represents the next generation in IVUS imaging."

While SyncVision is currently installed in multiple limited market release sites throughout the US and Europe, the company anticipates the full market release in later 2014.

The company is planning to share the SyncVision technology with a global audience next month at the EuroPCR meeting in Paris.

Volcano president and CEO Scott Huennekens said: "This system further bolsters our portfolio of recent innovative releases with the iFR modality, CORE Precision-Guided System, and CORE Control Pad, all of which work to help improve patient outcomes and customer productivity."